CERo Therapeutics Holdings logo

CERo Therapeutics HoldingsNASDAQ: CERO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 November 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$11.87 M
-89%vs. 3y high
19%vs. sector
-vs. 3y high
-vs. sector
-316%vs. 3y high
11%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Mon, 28 Oct 2024 23:03:43 GMT
$0.08+$0.00(+0.64%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CERO Latest News

CERo Therapeutics, Inc. Provides Corporate Update
globenewswire.com21 October 2024 Sentiment: POSITIVE

Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides the following corporate update to stockholders from Interim CEO Chris Ehrlich.

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
globenewswire.com02 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company's management team to support recently named interim CEO, Chris Ehrlich.   Andrew Albert “Al” Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer.

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
globenewswire.com25 September 2024 Sentiment: NEUTRAL

Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes

What type of business is CERo Therapeutics Holdings?

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.

What sector is CERo Therapeutics Holdings in?

CERo Therapeutics Holdings is in the Healthcare sector

What industry is CERo Therapeutics Holdings in?

CERo Therapeutics Holdings is in the Biotechnology industry

What country is CERo Therapeutics Holdings from?

CERo Therapeutics Holdings is headquartered in United States

When did CERo Therapeutics Holdings go public?

CERo Therapeutics Holdings initial public offering (IPO) was on 30 November 2021

What is CERo Therapeutics Holdings website?

https://www.cero.bio

Is CERo Therapeutics Holdings in the S&P 500?

No, CERo Therapeutics Holdings is not included in the S&P 500 index

Is CERo Therapeutics Holdings in the NASDAQ 100?

No, CERo Therapeutics Holdings is not included in the NASDAQ 100 index

Is CERo Therapeutics Holdings in the Dow Jones?

No, CERo Therapeutics Holdings is not included in the Dow Jones index

When was CERo Therapeutics Holdings the previous earnings report?

No data

When does CERo Therapeutics Holdings earnings report?

Next earnings report date is not announced yet